The San Diego-based biotech company, aTyr Pharma, Inc., released findings on March 30, 2016, from a Phase 1b/2 clinical trial of its experimental therapy Resolaris in adult facioscapulohumeral muscular dystrophy (FSHD) patients. While… Read More »
aTyr Pharma to advance Resolaris™ clinical programs
NIH funding for Facioscapulohumeral muscular dystrophy sets new record
We have some good news to share on National Institutes of Health funding for FSHD. As part of the FSH Society’s committee work in Washington, DC, we recently received FY2015… Read More »
FSH Society newly awarded grants
The FSH Society has awarded $598,242 in research funds from its August 2015 grant submission cycle. Details of the funded projects can be viewed on this page. These proposals received highest marks from… Read More »
Ultragenyx Pharmaceutical to sponsor FSHD drug development project
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Saint Louis University’s (SLU) Center for World Health and Medicine, announced that they… Read More »
Whole-Body MRI Yields New Insights
By June Kinoshita (from FSH Watch Fall 2015 issue) Click on image below to view full size. In 2013-2014, the FSH Society funded a study led by Doris Leung, MD,… Read More »